Non-alcoholic Fatty Liver Disease Development: A Multifactorial Pathogenic Phenomena

Overview

Journal Liver Res

Date 2025 Feb 17

PMID 39958625

Authors

Aamir Bashir

Ajay Duseja

Arka De

Manu Mehta

Pramil Tiwari

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD), characterized by the accumulation of excessive intrahepatic fat, is a leading metabolic disorder also considered as the hepatic manifestation of metabolic syndrome (MS). Though more commonly observed in obese individuals and those with metabolic risk factors, it also develops in a considerable number of non-obese individuals as well as participants without having any component of MS. The basic mechanism involved in the development of fatty liver is the imbalance between lipid uptake, synthesis, and metabolism in the liver, normally controlled by several mechanisms to maintain lipid homeostasis. As a complex progressive liver disorder, the NAFLD pathogenesis is multifactorial, and several new pathogenic phenomena were discovered over time. The available literature suggests the role of both genetic and environmental factors and associated metabolic factors; however, the mechanism of progression is not completely understood. In this review, we discuss different pathogenic mechanisms and their interplay to provide an elaborate idea regarding NAFLD development and progression. Better understanding of pathogenic mechanisms will be useful in finding new treatment for patients with NAFLD.

References

Sassi F, Tamone C, DAmelio P . Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients. 2018; 10(11). PMC: 6266123. DOI: 10.3390/nu10111656. View

Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati F, Potter J . Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013; 38(3):246-54. DOI: 10.1111/apt.12377. View

Mann J, Raponi M, Nobili V . Clinical implications of understanding the association between oxidative stress and pediatric NAFLD. Expert Rev Gastroenterol Hepatol. 2017; 11(4):371-382. DOI: 10.1080/17474124.2017.1291340. View

Ding L, Sousa K, Jin L, Dong B, Kim B, Ramirez R . Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice. Hepatology. 2016; 64(3):760-73. PMC: 4992413. DOI: 10.1002/hep.28689. View

Dornas W, Schuppan D . Mitochondrial oxidative injury: a key player in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2020; 319(3):G400-G411. DOI: 10.1152/ajpgi.00121.2020. View

Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R . Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014; 13(4):643-54.e1-9. PMC: 4208976. DOI: 10.1016/j.cgh.2014.04.014. View

Corbin K, Zeisel S . Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol. 2011; 28(2):159-65. PMC: 3601486. DOI: 10.1097/MOG.0b013e32834e7b4b. View

Ferri F, Mischitelli M, Tozzi G, Messina E, Mignini I, Mazzuca S . Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol. 2020; 11(2):e00116. PMC: 7145031. DOI: 10.14309/ctg.0000000000000116. View

Catrysse L, van Loo G . Inflammation and the Metabolic Syndrome: The Tissue-Specific Functions of NF-κB. Trends Cell Biol. 2017; 27(6):417-429. DOI: 10.1016/j.tcb.2017.01.006. View

10.

Mokhtari Z, Gibson D, Hekmatdoost A . Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Adv Nutr. 2017; 8(2):240-252. PMC: 5347097. DOI: 10.3945/an.116.013151. View

11.

Chen Z, Yu R, Xiong Y, Du F, Zhu S . A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017; 16(1):203. PMC: 5644081. DOI: 10.1186/s12944-017-0572-9. View

12.

Schugar R, Huang X, Moll A, Brunt E, Crawford P . Role of choline deficiency in the Fatty liver phenotype of mice fed a low protein, very low carbohydrate ketogenic diet. PLoS One. 2013; 8(8):e74806. PMC: 3756977. DOI: 10.1371/journal.pone.0074806. View

13.

Jonas W, Schurmann A . Genetic and epigenetic factors determining NAFLD risk. Mol Metab. 2020; 50:101111. PMC: 8324682. DOI: 10.1016/j.molmet.2020.101111. View

14.

Grohmann M, Wiede F, Dodd G, Gurzov E, Ooi G, Butt T . Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC. Cell. 2018; 175(5):1289-1306.e20. PMC: 6242467. DOI: 10.1016/j.cell.2018.09.053. View

15.

Kleiner D, Brunt E, Wilson L, Behling C, Guy C, Contos M . Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019; 2(10):e1912565. PMC: 6784786. DOI: 10.1001/jamanetworkopen.2019.12565. View

16.

Schaap F, Trauner M, Jansen P . Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2013; 11(1):55-67. DOI: 10.1038/nrgastro.2013.151. View

17.

Anwar H, Iftikhar A, Muzaffar H, Almatroudi A, Allemailem K, Navaid S . Biodiversity of Gut Microbiota: Impact of Various Host and Environmental Factors. Biomed Res Int. 2021; 2021:5575245. PMC: 8133857. DOI: 10.1155/2021/5575245. View

18.

Bashir A, Tiwari P, Duseja A . Enzyme replacement therapy in lysosomal acid lipase deficiency (LAL-D): a systematic literature review. Ther Adv Rare Dis. 2023; 2:26330040211026928. PMC: 10032452. DOI: 10.1177/26330040211026928. View

19.

Bashir A, Duseja A, Verma A, De A, Tiwari P . Lysosomal Acid Lipase Activity in Non-alcoholic Fatty Liver Disease as a Novel Diagnostic and Therapeutic Target: A Systematic Literature Review of Current Evidence and Future Directions. J Clin Exp Hepatol. 2022; 12(6):1535-1546. PMC: 9630019. DOI: 10.1016/j.jceh.2022.04.011. View

20.

Pierantonelli I, Svegliati-Baroni G . Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation. 2018; 103(1):e1-e13. DOI: 10.1097/TP.0000000000002480. View